Which antihypertensive drug is most commonly used in pregnancy?

NORCET 9 Mains - 2025

Pharmacology

Easy

Appeared in: NORCET 9 Mains - 2025

Explanation

Methyldopa is a centrally-acting alpha-2 adrenergic agonist that lowers blood pressure by reducing sympathetic outflow from the central nervous system.
It has the most extensive and longest safety record for use in treating chronic hypertension during pregnancy, making it a traditional first-line choice.
Unlike other antihypertensives, it has not been associated with significant adverse fetal outcomes when used as indicated.

Option B: Enalapril is an Angiotensin-Converting Enzyme (ACE) inhibitor. This class of drugs is absolutely contraindicated in pregnancy, particularly in the second and third trimesters.
Option C: Losartan is an Angiotensin II Receptor Blocker (ARB). Like ACE inhibitors, ARBs are contraindicated in pregnancy due to the high risk of causing severe fetal renal damage, oligohydramnios, and other malformations.
Option D: Atenolol is a beta-blocker that is generally avoided during pregnancy because it has been specifically linked to an increased risk of fetal growth restriction.

Visual 1: Flowchart: Management of Chronic Hypertension in Pregnancy, highlighting first-line (safe) agents like Methyldopa, Labetalol, and Nifedipine, and clearly marking contraindicated drugs like ACE inhibitors and ARBs.

Clinical Relevance

Nursing practice connection: Knowing Pharmacological management of hypertension during pregnancy helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
A key nursing responsibility is patient education for women of childbearing age with chronic hypertension. They must understand the teratogenic risks of ACE inhibitors and ARBs and the critical need for pre-conceptional counseling to switch to safer alternatives before becoming pregnant.
Nurses must diligently monitor for the development of superimposed preeclampsia in pregnant women with chronic hypertension, as this significantly increases maternal and fetal risks.
What if? If a pregnant patient with chronic hypertension develops a hypertensive emergency (e.g., systolic BP greater than 160 mmHg or diastolic BP greater than 110 mmHg), the first-line treatment is not oral Methyldopa but rather rapid-acting intravenous agents like Labetalol or Hydralazine to prevent maternal stroke.

How to Approach the Question

First, identify the key elements of the question: 'antihypertensive drug' and the specific patient population, 'pregnancy'.
Recognize that pregnancy is a special condition with significant implications for drug safety. Many medications are contraindicated.
Systematically review the options based on their safety profile in pregnancy. Start by eliminating drugs that are known to be teratogenic or absolutely contraindicated.
Recall that both ACE inhibitors (Enalapril) and ARBs (Losartan) are contraindicated in pregnancy due to the risk of severe fetal harm. This eliminates options B and C.
Compare the remaining options, Methyldopa and Atenolol. Recall that while both are antihypertensives, Atenolol is specifically associated with fetal growth restriction and is therefore avoided.
This leaves Methyldopa, which is well-known for its long history of safe use in managing chronic hypertension during pregnancy, making it the correct answer.

Concept Tested & Keywords

QITdQhcFLAwIOJCzq4StZf